JP7844491B2 - ヒドロキシヘテロシクロアルカン-カルバモイル誘導体 - Google Patents
ヒドロキシヘテロシクロアルカン-カルバモイル誘導体Info
- Publication number
- JP7844491B2 JP7844491B2 JP2023547852A JP2023547852A JP7844491B2 JP 7844491 B2 JP7844491 B2 JP 7844491B2 JP 2023547852 A JP2023547852 A JP 2023547852A JP 2023547852 A JP2023547852 A JP 2023547852A JP 7844491 B2 JP7844491 B2 JP 7844491B2
- Authority
- JP
- Japan
- Prior art keywords
- pyran
- hydroxy
- carboxamide
- hydroxymethyl
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021053084 | 2021-02-09 | ||
| EPPCT/EP2021/053084 | 2021-02-09 | ||
| PCT/EP2022/052948 WO2022171594A1 (en) | 2021-02-09 | 2022-02-08 | Hydroxyheterocycloalkane-carbamoyl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506182A JP2024506182A (ja) | 2024-02-09 |
| JP2024506182A5 JP2024506182A5 (cg-RX-API-DMAC7.html) | 2025-02-17 |
| JP7844491B2 true JP7844491B2 (ja) | 2026-04-13 |
Family
ID=80445748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547852A Active JP7844491B2 (ja) | 2021-02-09 | 2022-02-08 | ヒドロキシヘテロシクロアルカン-カルバモイル誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12304902B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291556B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7844491B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230145111A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116806219A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022221092A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3207214A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023002322A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3032987T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304923A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202246248A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022171594A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202308643B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519625A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC | 疾患の予防および治療用の化合物およびその使用 |
| WO2020210308A1 (en) | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| JP2023547241A (ja) | 2020-11-02 | 2023-11-09 | イドーシア ファーマシューティカルズ リミテッド | ガレクチン-3を阻害する2-ヒドロキシシクロアルカン-1-カルバモイル誘導体 |
| JP7604457B2 (ja) | 2019-08-15 | 2024-12-23 | イドルシア・ファーマシューティカルズ・リミテッド | 2-ヒドロキシシクロアルカン-1-カルバモイル誘導体 |
| JP7612669B2 (ja) | 2019-08-29 | 2025-01-14 | イドルシア・ファーマシューティカルズ・リミテッド | アルファ-d-ガラクトピラノシド誘導体 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (cg-RX-API-DMAC7.html) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CN109563119A (zh) | 2016-07-12 | 2019-04-02 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2022
- 2022-02-08 JP JP2023547852A patent/JP7844491B2/ja active Active
- 2022-02-08 IL IL304923A patent/IL304923A/en unknown
- 2022-02-08 EP EP22703412.1A patent/EP4291556B1/en active Active
- 2022-02-08 TW TW111104468A patent/TW202246248A/zh unknown
- 2022-02-08 CA CA3207214A patent/CA3207214A1/en active Pending
- 2022-02-08 WO PCT/EP2022/052948 patent/WO2022171594A1/en not_active Ceased
- 2022-02-08 US US18/264,751 patent/US12304902B2/en active Active
- 2022-02-08 ES ES22703412T patent/ES3032987T3/es active Active
- 2022-02-08 KR KR1020237030395A patent/KR20230145111A/ko active Pending
- 2022-02-08 AU AU2022221092A patent/AU2022221092A1/en active Pending
- 2022-02-08 CN CN202280013265.8A patent/CN116806219A/zh active Pending
-
2023
- 2023-08-07 CL CL2023002322A patent/CL2023002322A1/es unknown
- 2023-09-08 ZA ZA2023/08643A patent/ZA202308643B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519625A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC | 疾患の予防および治療用の化合物およびその使用 |
| WO2020210308A1 (en) | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| JP7604457B2 (ja) | 2019-08-15 | 2024-12-23 | イドルシア・ファーマシューティカルズ・リミテッド | 2-ヒドロキシシクロアルカン-1-カルバモイル誘導体 |
| JP7612669B2 (ja) | 2019-08-29 | 2025-01-14 | イドルシア・ファーマシューティカルズ・リミテッド | アルファ-d-ガラクトピラノシド誘導体 |
| JP2023547241A (ja) | 2020-11-02 | 2023-11-09 | イドーシア ファーマシューティカルズ リミテッド | ガレクチン-3を阻害する2-ヒドロキシシクロアルカン-1-カルバモイル誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116806219A (zh) | 2023-09-26 |
| EP4291556C0 (en) | 2025-04-23 |
| EP4291556B1 (en) | 2025-04-23 |
| WO2022171594A1 (en) | 2022-08-18 |
| CL2023002322A1 (es) | 2024-03-08 |
| KR20230145111A (ko) | 2023-10-17 |
| CA3207214A1 (en) | 2022-08-18 |
| IL304923A (en) | 2023-10-01 |
| ZA202308643B (en) | 2026-03-25 |
| ES3032987T3 (en) | 2025-07-29 |
| AU2022221092A1 (en) | 2023-09-21 |
| US20240124427A1 (en) | 2024-04-18 |
| TW202246248A (zh) | 2022-12-01 |
| JP2024506182A (ja) | 2024-02-09 |
| US12304902B2 (en) | 2025-05-20 |
| EP4291556A1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102832308B1 (ko) | 2-히드록시시클로알칸-1-카르바모일 유도체 | |
| JP7834746B2 (ja) | ガレクチン-3を阻害する2-ヒドロキシシクロアルカン-1-カルバモイル誘導体 | |
| EP4291556B1 (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| JP7612663B2 (ja) | (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体 | |
| JP7757399B2 (ja) | アルファ-d-ガラクトピラノシドのスピロ誘導体 | |
| HK40101885B (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| HK40101885A (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| EA048927B1 (ru) | Гидроксигетероциклоалканкарбамоильные производные | |
| CN116745282A (zh) | 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3 | |
| EA050798B1 (ru) | 2-гидроксициклоалкан-1-карбамоильные производные, ингибирующие галектин-3 | |
| HK40071801B (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| HK40071801A (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| EA048291B1 (ru) | 2-гидроксициклоалкан-1-карбамоильные производные |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251202 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260226 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20260226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260303 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260401 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7844491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |